Research Topics
Species | Robert W VeltriSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Nuclear morphometry, nucleomics and prostate cancer progressionRobert W Veltri
Fisher Biomarker and Biorepository Laboratory, The Brady Urological Research Institute, Baltimore, MD 21287, USA
Asian J Androl 14:375-84. 2012..These series of cellular and tissue-related malignancy-associated events can be quantified to assess disease progression and management...
Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostateRobert W Veltri
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Clin Cancer Res 10:3465-73. 2004..The nuclear structure information was combined with routine pathological findings to predict metastatic PCa progression and/or death...
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesisRobert W Veltri
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Prostate 68:1806-15. 2008..Therefore, we evaluated the prognostic value of these parameters in 105 clinically localized PCa tumors with long-term follow-up after radical prostatectomy for progression-free survival (PFS)...- Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysisRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Prostate 67:1202-10. 2007..Quantitative Nuclear Morphometry (QNM) profiles were created to evaluate variability in nuclear structure within each of these grades... - Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American menR W Veltri
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Prostate Cancer Prostatic Dis 7:232-7. 2004.... - Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomyRobert W Veltri
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Prostate 70:1333-9. 2010..Therefore, we evaluated the prognostic value of nuclear roundness variance (NRV) for prostate cancer (PCa) progression, metastasis and PCa-specific death free survivals in a cohort of 116 men after radical prostatectomy (RP)... - Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancerRobert W Veltri
Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Urology 60:47-52. 2002..0 to 20.0 ng/mL. This study demonstrated that to maintain a given sensitivity level for cPSA and tPSA in the age ranges studied, continuous upward adjustment of the cutoffs was required as age increased... - Nucleic acid-based marker approaches to urologic cancersRobert W Veltri
Department of Urology, The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2101, USA
Urol Oncol 24:510-27. 2006..We review only nucleic acid-based molecular biomarkers in urologic oncology that can assist the clinician in establishing the diagnosis of disease, or that can predict the behavior of the disease or the patient's survival... - Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stageRobert W Veltri
Johns Hopkins Hospital, Department of Urology, 600 North Wolfe St, Baltimore, MD 21287, USA
Clin Chem 48:1828-34. 2002..This study compares statistical and neural network (NN) approaches to predict PCa stage... - Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometryRobert W Veltri
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Cancer Epidemiol Biomarkers Prev 17:102-10. 2008.... - DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer predictionSumit Isharwal
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
Urology 73:1092-7. 2009..To evaluate nuclear morphometric alterations and clinicopathologic features for organ- vs nonorgan-confined prostate carcinoma (PCa) prediction... - Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intentDanil V Makarov
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Prostate 68:183-9. 2008..We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort... - Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomyMasood A Khan
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Cancer 98:2583-91. 2003..QNG solutions can serve as a new supplemental biomarker for accurate prediction of PCa progression at the time of surgery... - Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancerRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Urology 68:898-904. 2006..These preliminary observations indicate a basis for biologic and molecular alterations in the benign adjacent and malignant epithelium between these two groups... - Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomySumit Isharwal
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Int J Cancer 123:2636-43. 2008..Further, Her-2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of long-term prognosis in PCa... - Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trialLeonard S Marks
Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
JAMA 296:2351-61. 2006..Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men... - p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shapeSumit Isharwal
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Prostate 68:1097-104. 2008..Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long-term follow-up after radical prostatectomy (RP)... - DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programmeSumit Isharwal
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
BJU Int 105:329-33. 2010..Study Type - Prognosis (case series)Level of Evidence 4... - ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance programSumit Isharwal
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Urology 77:763.e1-6. 2011.... - Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?Masood A Khan
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
J Urol 170:2274-8. 2003..Therefore, we determined whether biomarkers could be used to determine those in whom disease is likely to progress and thus those who require definitive therapy... - Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challengeRobert W Veltri
Brady Urological Institute of The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA
J Urol 168:100-4. 2002..4%. CONCLUSIONS: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data... - Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissueLeonard S Marks
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
Urology 64:765-71. 2004..Differences in nuclear morphometry suggested the additional possibility of gene-nutrient interactions... - Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomyCraig G Rogers
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Cancer 101:2549-56. 2004..The authors assessed the clinical outcome of men with a persistently detectable PSA level after RRP for clinically localized prostate carcinoma... - Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation studyAlexander Haese
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Cancer 97:969-78. 2003..2-90.2% of patients. These data support the use of quantitative pathology and clinical data-based decision modeling to manage patients with clinically localized PCa... - Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/mlMasood A Khan
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
J Urol 170:723-6. 2003..CONCLUSIONS: Sum-proPSA, total PSA and %fPSA in combination improve the specificity of early prostate cancer detection in men with a total PSA of 4 to 10 ng/ml compared with the results of individual PSA molecular forms measured... - Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American menJae Park
James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Marburg 409, 600 North Wolfe Street, Baltimore, MD 21287, USA
Clin Prostate Cancer 2:173-6. 2003..In a contemporary screening population comparing tPSA, percentage of fPSA, and percentage of cPSA levels in 3 races, there were no significant differences identified among the groups... - Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanismRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Urology 60:617-22. 2002..Thus, a possible molecular basis for tissue changes and therapeutic effect of the compound is suggested... - Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screeningLars Ellison
Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, Maryland 21287, USA
Urology 60:42-6. 2002..8 ng/mL. The use of cPSA with a threshold of 3.0 ng/mL identifies a similar number of cancers with fewer biopsies than tPSA at 4.0 ng/mL... - Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice studyJoseph C Presti
Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
J Urol 169:125-9. 2003..Generally increasing patient age and PSA were associated with larger, higher grade tumors. Extended biopsy schemes minimize PSA and age related detection rates... - Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivoMadeleine S Q Kortenhorst
Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, James Buchanan Brady Urological Institute, School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
Mol Cancer Ther 8:802-8. 2009..Therefore, nuclear structural alterations may serve as a biomarker for histone deacetylase inhibitor treatment... - Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infectionXiaoli Zhong
Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
PLoS ONE 8:e59089. 2013..Here we evaluated aberrant promoter DNA methylation as a potential biomarker to detect severe bladder damage that is associated with schistosomiasis by analyzing urine specimens... - Non-invasive methods to detect schistosome-based bladder cancer: is the association sufficient for epidemiological use?Clive Shiff
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Trans R Soc Trop Med Hyg 104:3-5. 2010..We suggest that early diagnosis of pre-cancerous conditions associated with urinary schistosomiasis, if appropriately treated, could save countless lives... - Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerRong Hu
Department of Urology, Oncology, and Pathology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
Cancer Res 69:16-22. 2009..In addition, as expression markers for lethal PCa, these novel AR variants may be explored as potential biomarkers and therapeutic targets for advanced PCa... - Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancerScott M Gilbert
Department of Urology, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA
Urology 61:539-43. 2003..In addition, DD23 does not appear to lose sensitivity in patients with a prior history of bladder cancer treated with intravesical agents... - Clinical utility of squamous and transitional nuclear structure alterations induced by Schistosoma haematobium in chronically infected adults with bladder damage verified by ultrasound in GhanaJean Naples
Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Anal Quant Cytol Histol 31:143-52. 2009..e., alteration in nuclear size/shape, DNA content and chromatin structure-of intact cells obtained from the sediment of urine specimens collected from people living in an area highly endemic for Schistosoma haematobium in Ghana... - Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancerJohn J Kim
Department of Urology, James Buchanan Brady Urological Institute, Baltimore, Maryland 21287 Department of Biomedical Engineering, Whiting School of Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287
J Cell Biochem 114:1286-93. 2013..J. Cell. Biochem. 114: 1286-1293, 2013. © 2012 Wiley Periodicals, Inc... - Urinary markers in the detection of bladder cancer: what's new?Matthew E Nielsen
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
Curr Opin Urol 16:350-5. 2006..In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection... - Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOFM B Gretzer
The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Prostate 60:325-31. 2004.... - Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinomaAi Ying Chuang
Department of Pathology, Koo Foundation Sun Yat Sen Cancer Center, Taipei, Taiwan
Am J Surg Pathol 31:1246-55. 2007..1, and pPSA are useful when high-grade prostate cancer is suspected based on the morphology or clinical findings, yet shows negative or equivocal PSA staining. HMWCK and p63 are superior to the novel markers thrombomodulin and S100P... - SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progressionGunjan Malik
Center for Biomedical Proteomics, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, Virginia, USA
Prostate 67:1565-75. 2007..As a parallel effort, we have been pursuing the identification of the protein(s) comprising the individual discriminatory "peaks" and evaluating their utility as potential biomarkers for prostate cancer progression... - Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancerAnil V Parwani
Division of Pathology Informatics and Genito Urinary Pathology, Univeristy of Pittsburgh Medical Center Shadyside Hospital, Department of Pathology, Pittsburgh, PA 15232, USA
Am J Surg Pathol 30:1231-6. 2006..A panel of markers, including proPSA, should be performed when metastatic prostate carcinoma is in the differential diagnosis... - DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCCIhor S Sawczuk
Columbia University, Urology Department, 161 Fort Washington Ave, New York, NY 10032, USA
Urol Oncol 7:185-90. 2002..A prospective clinical study was conducted to assess the ability of the DD23 murine monoclonal antibody to enhance detection of bladder cancer in routine alcohol fixed urine cytology samples...